Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chuanhuang Formula 1 is a Traditional Chinese Medicine (TCM) herbal formulation developed by Shanghai East Hospital for the treatment of primary IgA nephropathy (IgAN), specifically for patients in stage 3 chronic kidney disease (CKD). It is typically administered as an adjunctive therapy alongside standard Western treatments such as the angiotensin II receptor blocker valsartan. The formula is designed to reduce proteinuria and preserve renal function by leveraging the synergistic effects of its constituent botanical ingredients, which are traditionally used to address kidney deficiency and blood stasis. Clinical evaluation is focused on its efficacy and safety in improving renal outcomes compared to valsartan monotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chuanhuang Formula 1.